Conformational Equilibrium of Heparin-Like Trisaccharides
FULL PAPER
11.5 Hz, 1H; PhCH), 4.85 (d, J1,2 =4.0 Hz, 1H; H1a), 4.83 (brd, J5,4
2.0 Hz, 1H; H5b), 4.78 (d, J=11.5 Hz, 1H; PhCH), 4.75 (s, 2H; PhCH2),
4.60 (ABsystem, 2H; PhCH2), 4.57 (d, J=12.0 Hz, 1H; PhCH), 4.40 (dd,
=
AcOH) Rf =0.61; MS (ESI): m/z positive mode: 1173.4 [M+Na]+, 1151.4
[M+H]+; m/z negative mode: 1149.4 [MꢀH]ꢀ, 1127.4 [MꢀNa]ꢀ). Trie-
thylamine (0.5 mL) and sulfur trioxide-pyridine complex (19 mg,
0.12 mmol) were added to a solution of the crude in pyridine (2.5 mL),
After stirring for 30 min at RT under argon atmosphere, the solution was
purified by Sephadex LH-20 (MeOH/CH2Cl2 =1:1), C-18 reverse phase
chromatography (0% to 100% of MeOH in a 10 mm Et3NHOAc aq. sol-
ution), again Sephadex LH-20 column (MeOH/CH2Cl2 =1:1), and finally
passed through a Dowex 50WX4-Na+ column (MeOH/H2O=9:1) to give
22 (24 mg, 82%). Characterization of 22 as triethylammonium salt:
[a]2D0 =+25.708 (c=1.0, MeOH); TLC (15/5/3/1 EtOAc/Py/H2O/AcOH)
Rf =0.30; 1H NMR (500 MHz, CD3OD): d=7.52 (brt, J=7.5 Hz, 4H;
PhH), 7.49 (brd, J=7.5 Hz, 2H; PhH), 7.44 (m, 2H; PhH), 7.38–7.16 (m,
14H; PhH), 7.18 (brt, J=7.5 Hz, 1H; PhH), 7.13 (brd, J=7.5 Hz, 2H;
PhH), 5.58 (s, 1H; PhCHO2), 5.57 (brs, 1H; H1b), 5.48 (d, J1,2 =3.5 Hz,
1H; H1c), 5.05 (d, J=12.5 Hz, 1H; PhCH), 4.96 (brs, 1H; H5b), 4.94 (d,
J=12.5 Hz, 1H; PhCH), 4.91 (d, J=12.0 Hz, 1H; PhCH), 4.84 (ABsys-
tem, 2H; PhCH2), 4.83 (d, J1,2 =3.5 Hz, 1H; H1a), 4.78 (d, J=11.5 Hz,
1H; PhCH), 4.72 (brs, 1H; H2b), 4.58 (d, J=11.5 Hz, 1H; PhCH), 4.52
(brs, 1H; H3b), 4.46 (dd, J6,5 =5.0 Hz, J6,6’ =10.0 Hz, 1H; H6c), 4.38 (d, J=
13.0 Hz, 1H; PhCH), 4.29 (brs, 1H; H4b), 4.28 (brd, J6,6’ =11.0 Hz, 1H;
J
6,5 =5.0 Hz, J6,6’ =10.0 Hz, 1H; H6c), 4.38 (brt, J4,3 =J4,5 =3.0 Hz, 1H;
H4b), 4.15 (td, J5,6 =5.5 Hz, J5,4 =J5,6’ =10.0 Hz, 1H; H5c), 4.14 (t, J3,2
3,4 =9.5 Hz, 1H; H3c), 4.10 (dd, J2,1 =3.5 Hz, J2,3 =10.5 Hz, 1H; H2a), 3.95
=
J
(m, 1H; H3b), 3.94 (m, 2H; H4a +H5a), 3.89 (m, 1H; H6a), 3.88 (hept, J=
6.0 Hz, 1H; CH iPr), 3.82 (m, 1H; H3a), 3.81 (brt, J2,1 =J2,3 =3.0 Hz, 1H;
H2b), 3.731 (dd, J2,1 =4.0 Hz, J2,3 =10.0 Hz, 1H; H2c), 3.728 (m, 1H; H6a’),
3.72 (t, J4,3 =J4,5 =9.5 Hz, 1H; H4c), 3.69 (t, J6’,5 =J6’,6 =10.0 Hz, 1H; H6c’),
1.77 (s, 3H; CH3CONH), 1.25 (d, J=6.0 Hz, 3H; CH3 iPr), 1.15 ppm (d,
J=6.0 Hz, 3H; CH3 iPr); 13C NMR (125 MHz, CD3OD): d=173.30,
173.18 (C=O), 140.15 (C Ph), 139.47 (3ꢅC Ph), 139.05 (C Ph), 129.89,
129.40, 129.27, 129.18, 129.12, 129.08, 129.05, 129.02, 128.84, 128.72,
128.66, 128.41, 128.18, 127.25 (CH Ph), 103.56 (C1b), 102.44 (PhCHO2),
97.16 (C1c), 96.87 (C1a), 83.57 (C4c), 80.67 (C3a), 79.00 (C3c), 78.67 (C3b),
76.09 (C4a), 75.87, 75.41 (PhCH2), 74.79 (C4b), 74.44, 73.18 (PhCH2), 72.24
(C5a), 71.34 (C5b), 71.31 (CH iPr), 70.09 (C6a), 69.59 (C2b +C6c), 65.13
(C2c), 64.22 (C5c), 54.50 (C2a), 23.67 (CH3 iPr), 22.60 (CH3CONH),
21.61 ppm (CH3 iPr). MS (ESI) m/z positive mode: 1197.3 [M+Na]+; m/z
negative mode: 1073.4 [MꢀH]ꢀ.
H6a), 4.10 (td, J5,6 =5.0 Hz, J5,4 =J5,6’ =10.0 Hz, 1H; H5c), 3.95 (dd, J2,1
=
Isopropyl O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-a-d-gluco-
pyranosyl)-(1!4)-O-(3-O-benzyl-2-O-sulfo-a-l-idopyranosyluronic acid)-
(1!4)-2-acetamido-2-deoxy-3,6-di-O-benzyl-a-d-glucopyranoside triethyl-
ammonium salt (18): Sulfur trioxide-trimethylamine complex (46 mg,
0.33 mmol) was added to a solution of 14 (36 mg, 0.033 mmol) in dry
DMF (3.3 mL). After stirring for 72 h at 508C under argon atmosphere,
Et3N (100 mL) was added and the solution stirred at RT for 5 min. The
solution was purified by Sephadex LH-20 chromatography (MeOH/
CH2Cl2 =1:1), and C-18 reverse phase chromatography (0% to 100% of
MeOH in a 10 mm Et3NHOAc aq. solution) to give 18 (35 mg, 78%).
[a]2D0 =+16.148 (c=1.4, MeOH); TLC (60/5/3/1 EtOAc/Py/H2O/AcOH)
Rf =0.30; 1H NMR (500 MHz, CD3OD): d=7.53–7.46 (m, 6H; PhH),
7.41–7.23 (m, 16H; PhH), 7.21–7.17 (m, 3H; PhH), 5.62 (s, 1H;
PhCHO2), 5.44 (brs, 1H; H1b), 5.12 (brs, 1H; H1c), 4.96 (brs, 1H; H5b),
4.95–4.87 (m, 3H; 3ꢅPhCH), 4.84 (d, J1,2 =3.5 Hz, 1H; H1a), 4.80 (d, J=
11.5 Hz, 1H; PhCH), 4.77 (d, J=11.5 Hz, 1H; PhCH), 4.73 (d, J=
11.0 Hz, 1H; PhCH), 4.67 (brs, 1H; H2b), 4.60 (d, J=12.0 Hz, 1H;
PhCH), 4.51 (d, J=12.5 Hz, 1H; PhCH), 4.31 (brd, J6,6’ =10.0 Hz, 1H;
H6c), 4.30 (brt, J3,2 =J3,4 =4.0 Hz, 1H; H3b), 4.22 (brs, 1H; H4b), 4.13
(brd, J6,6’ =11.0 Hz, 1H; H6a), 4.08 (m, 1H; H2a), 4.01 (m, 1H; H3c), 4.00
(m, 1H; H5c), 3.98 (t, J4,3 =J4,5 =9.5 Hz, 1H; H4a), 3.94 (brd, J5,4 =10.0 Hz,
1H; H5a), 3.89 (hept, J=6.0 Hz, 1H; CH iPr), 3.76 (t, J3,2 =J3,4 =9.5 Hz,
1H; H3a), 3.75 (brd, J6’,6 =11.0 Hz, 1H; H6a’), 3.73 (t, J4,3 =J4,5 =10.0 Hz,
1H; H4c), 3.70 (brd, J6’,6 =10.0 Hz, 1H; H6c’), 3.53 (brd, J2,3 =10.0 Hz,
1H; H2c), 2.99 (brq, J=7.0 Hz, 12H; CH2 Et3NH+), 1.68 (s, 3H;
CH3CONH), 1.26 (d, J=6.5 Hz, 3H; CH3 iPr), 1.18 (brt, J=7.0 Hz, 18H;
CH3 Et3NH+), 1.16 ppm (d, J=6.0 Hz, 3H; CH3 iPr); 13C NMR
(125 MHz, CD3OD): d=174.91, 173.13 (C=O), 140.65, 140.02, 139.87,
139.62, 139.27 (C Ph), 129.74, 129.39, 129.33, 129.26, 129.11, 129.04,
128.95, 128.71, 128.62, 128.54, 128.35, 128.03, 127.16 (CH ꢆ Ph), 102.18
(PhCHO2), 100.61 (C1b), 97.61 (C1c), 96.97 (C1a), 83.67 (C4c), 80.64 (C3a),
78.42 (C3c), 76.64 (C4a), 75.71, 75.42, 74.20 (PhCH2), 73.28 (C3b), 73.08
(C4b), 73.02 (PhCH2), 72.51 (C5a), 72.04 (C2b), 71.35 (CH iPr), 69.83 (C6a),
69.67 (C6c), 69.13 (C5b), 64.92 (C2c), 64.21 (C5c), 54.82 (C2a), 47.41
(CH2 Et3NH+), 23.65 (CH3 iPr), 22.46 (CH3CONH), 21.66 (CH3 iPr), 9.16
3.5 Hz, J2,3 =10.5 Hz, 1H; H2a), 3.91 (m, 2H; H4a +H5a), 3.87 (hept, J=
6.0 Hz, 1H CH iPr), 3.75 (t, J3,2 =J3,4 =9.5 Hz, 1H; H3c), 3.71 (m, 2H;
H
3a +H6a’), 3.64 (t, J6’,6 =J6’,5 =10.5 Hz, 1H; H6c’), 3.62 (t, J4,3 =J4,5 =
10.5 Hz, 1H; H4c), 3.59 (dd, J2,1 =3.5 Hz, J2,3 =10.0 Hz, 1H; H2c), 2.99 (q,
J=7.5 Hz, 18H; CH2 Et3NH+), 1.55 (s, 3H; CH3CONH), 1.25 (d, J=
6.0 Hz, 3H; CH3 iPr), 1.20 (t, J=7.5 Hz, 27H; CH3 Et3NH+), 1.13 ppm
(d, J=6.0 Hz, 3H; CH3 iPr); 13C NMR (100 MHz, CD3OD): d=176.17,
173.06 (C=O), 141.08, 140.94, 140.45, 140.24, 139.72 (C Ph), 129.50,
129.39, 129.28, 129.18, 129.10, 129.06, 129.03, 128.96, 128.91, 128.69,
128.53, 128.35, 128.09, 127.98, 127.12 (CH Ph), 102.35 (C1c), 101.77
(PhCHO2), 100.00 (C1b), 96.90 (C1a), 83.27 (C4c), 80.84 (C3a), 78.47 (C4b),
78.25 (C3c), 76.57 (C3b +C4a), 75.95, 75.60, 74.23, 73.02 (PhCH2), 72.68
(C2b +C5a), 71.30 (CH iPr), 69.97 (C6a), 69.91 (C5b), 69.85 (C6c), 64.34
(C5c), 60.78 (C2c), 55.06 (C2a), 47.41 (CH2 Et3NH+), 23.64 (CH3 iPr), 22.45
(CH3CONH), 21.65 (CH3 iPr), 9.42 ppm (CH3 Et3NH+); MS (ESI): m/z
positive
mode:
1291.3
[Mꢀ3Et3NH+2Na+K+H]+,
1247.7
[Mꢀ3Et3NH+K+3H]+, 1231.8 [Mꢀ3Et3NH+Na+3H]+.
Isopropyl
O-(2-deoxy-2-sulfamido-a-d-glucopyranosyl)-(1!4)-O-(2-O-
sulfo-a-l-idopyranosyluronic acid)-(1!4)-2-acetamido-2-deoxy-a-d-glu-
copyranoside sodium salt (Tri8): A solution of 22 (24 mg, 0.019 mmol) in
a MeOH/H2O=9:1 mixture (3.8 mL) was hydrogenated in the presence
of 20% Pd(OH)2/C. After 18 h, the suspension was filtered through a
pad of celite and lyophilized to give Tri8 (15 mg, 96%). [a]2D0 =+66.08
(c=0.5, H2O); TLC (5/5/3/1 EtOAc/Py/H2O/AcOH) Rf =0.29; 1H NMR
(500 MHz, D2O): d=5.32 (d, J1,2 =3.5 Hz, 1H; H1c), 5.15 (d, J1,2 =3.0 Hz,
1H; H1b), 4.92 (d, J1,2 =3.5 Hz, 1H; H1a), 4.69 (d, J5,4 =2.5 Hz, 1H; H5b),
4.25 (dd, J2,1 =3.0 Hz, J2,3 =5.5 Hz, 1H; H2b), 4.16 (dd, J3,2 =4.0 Hz, J3,4
=
5.5 Hz, 1H; H3b), 4.03 (t, J4,3 =J4,5 =3.5 Hz, 1H; H4b), 3.84 (hept, J=
6.0 Hz, 1H; CH iPr), 3.83 (m, 3H, H5a +H6a +H6a’), 3.82 (dd, J2,1 =4.0 Hz,
J
2,3 =9.5 Hz, 1H; H2a), 3.80 (dd, J6,5 =2,0 Hz, J6,6’ =12.0 Hz, 1H; H6c), 3.77
(m, 2H; H4a +H5c), 3.72 (dd, J6’,5 =4.5 Hz, J6’,6 =12.0 Hz, 1H; H6c’), 3.65
(t, J3,2 =J3,4 =9.0 Hz, 1H; H3a), 3.58 (dd, J3,4 =9.5 Hz, J3,2 =10.5 Hz, 1H;
H3c), 3.39 (t, J4,3 =J4,5 =9.5 Hz, 1H; H4c), 3.15 (dd, J2,1 =3.5 Hz, J2,3
=
10.5 Hz, 1H; H2c), 1.97 (s, 3H; CH3CONH), 1.15 (d, J=6.0 Hz, 3H;
CH3 iPr), 1.07 ppm (d, J=6.0 Hz, 3H; CH3 iPr); 13C NMR (125 MHz,
D2O): d=176.26, 175.75 (C=O), 100.63 (C1b), 98.14 (C1c), 96.25 (C1a),
78.94 (C3a), 77.20 (C2b), 77.07 (C4b), 73.09 (C5c), 72.43 (C3c), 72.27
(CH iPr), 71.31 (C4c), 70.91 (C4a +C5a), 70.36 (C5b), 70.01 (C3b), 61.68
(C6c), 61.39 (C6a), 59.44 (C2c), 55.40 (C2a), 23.65 (CH3 iPr), 23.19
(CH3CONH), 21.86 ppm (CH3 iPr); MS (ESI): m/z positive mode: 849.1
[M+Na]+, 843.1 [MꢀNa+K+H]+; m/z negative mode: 803.1 [MꢀNa]ꢀ,
(CH3 Et3NH+);
MS
(ESI):
m/z
positive
mode:
1215.4
[Mꢀ2Et3NH+Na+K+H]+, 619.2 [Mꢀ2Et3NH+2Na+K+H]2+; m/z nega-
tive mode: 1153.5 [Mꢀ2Et3NH+H]ꢀ.
Isopropyl O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-sulfamido-a-d-glu-
copyranosyl)-(1!4)-O-(3-O-benzyl-2-O-sulfo-a-l-idopyranosyluronic
acid)-(1!4)-2-acetamido-2-deoxy-3,6-di-O-benzyl-a-d-glucopyranoside
sodium salt (22): An aqueous NaOH solution (1.9 mL; 0.1 N) and then a
trimethylphosphine THF solution (184 mL; 1.0m) were added dropwise to
a solution of 18 (31 mg, 0.023 mmol) in THF (2.3 mL) at 08C and the
mixture was stirred at RT. After 4 h, the solution was neutralized with an
aqueous HCl solution (0.1 N), the solvents were evaporated until dryness
and the resulting crude was suspended in MeOH, filtered, concentrated,
and dried under high vacuum overnight (TLC (60/5/3/1 EtOAc/Py/H2O/
797.1 [Mꢀ3Na+K+H]ꢀ, 781.1 [Mꢀ2Na+H]ꢀ, 390.0 [Mꢀ2Na]2ꢀ
.
NMR: NMR experiments were performed on Bruker DRX 500 MHz
spectrometer equipped with 5 mm inverse triple-resonance probe. NMR
samples were prepared at pH*’7 in 500–600 or 200 mL in 5 mm or 3 mm
tubes, at 2 mm and 6 mm, respectively, in 99.9% D2O and at several tem-
peratures varying from 278 to 318 K. Sizes of acquisition matrices were
Chem. Eur. J. 2012, 18, 16319 – 16331
ꢃ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
16329